On December 11, 2025, Oruka Therapeutics, Inc. announced that Cameron Turtle resigned from the Board of Directors, and Christopher Martin was appointed as a new director with a board term expiring in 2026. Martin is granted stock options for 35,000 shares and an annual compensation totaling $59,500.